Trial ID 21462 | Maryland Oncology Hematology Trial ID 21462 – Maryland Oncology Hematology

Trial ID 21462

Trial Information - Phase III

FLAMINGO-01: A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy

Disease Specifics: (HER2+)

Protocol ID: GLSI-21-01

Sponsor: Greenwich Life Sciences

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Breast

Investigator

Werner MD, Jeanine

Status

OPEN TO ENROLLMENT

Sponsor

Greenwich Life Sciences

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology